Lymphoma clinical trials in Montana

8 actively recruiting lymphoma trials at 6 sites across Montana.

Data from ClinicalTrials.gov · last refreshed 2026-08-10

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Loxo Oncology, Inc. funds and runs this clinical trial (NCT05254743). In 2024, Loxo Oncology, Inc. reported paying the doctors leading the trial a total of $2,037,139 for research work on this study.

Who paid

Eli Lilly and Company $2,037,139

Paid for research work on this trial

RICHY AGAJANIAN(oncologist on CancerDrs) $243,858
SALEHA SAJID(oncologist on CancerDrs) $165,169
CHANH HUYNH(oncologist on CancerDrs) $153,966
BRUCE CHESON(oncologist on CancerDrs) $152,368
JENNIFER CULTRERA(oncologist on CancerDrs) $151,740

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04269902

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Saint Vincent Healthcare — Billings, Montana
Saint Vincent Frontier Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT07321652

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Logan Health Medical Center — Kalispell, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06136559

Sites in Montana:

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052) — Billings, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.

NCT ID: NCT05254743

Sites in Montana:

St. Vincent Frontier Cancer Center — Billings, Montana

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearran…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06649812

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Community Medical Center — Missoula, Montana

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06890884

Sites in Montana:

Bozeman Health Deaconess Hospital ( Site 0183) — Bozeman, Montana

View on ClinicalTrials.gov →

Recruiting Network

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06002828

Sites in Montana:

Saint Patrick Hospital - Community Hospital — Missoula, Montana

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Montana:

Massive Bio SYNERGY-AI site — Billings, Montana

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10